Vertical displacement of syringe pumps may cause irregular drug delivery due to hydrostatic pressure changes in the infusion line. The extent of flow fluctuations depends on the internal compliance of infusion lines, syringes and syringe pumps. We evaluated whether pressure regulation by antisiphon valves (ASV) reduces the flow variation during vertical displacement of 50 ml standard syringes and infusion pumps.
In critically ill neonates and children, highly concentrated inotropic or vasoactive drugs are often applied using very low infusion rates (0.5 to 2 ml/h) to avoid volume overload. Vertical displacement of the infusion pump (e.g., in preparation for transport) results in potentially relevant flow irregularities, in particular zero-drug delivery times and infusion boluses [1] [2] [3] . These irregularities can cause serious haemodynamic disturbances and therefore should be avoided when vasoactive drugs are infused 1 .
The extent of these flow fluctuations depends on the internal compliance of syringes, infusion lines and syringe pumps during hydrostatic pressure changes 3, 4 . We hypothesized that the increased operating pressure by introducing antisiphon valves might preexpand the syringe system and reduce residual compliance. We further hypothesized that the lower compliance after pre-extension of the infusion system would translate to relevant reductions of the size of aspiration boluses, zero-drug delivery times and infusion boluses during moderate vertical displacement of the syringe pump.
The aim of this study was to evaluate the effect of two different antisiphon valves (ASV) on the performance of syringe-syringe pump assemblies during vertical displacement, using commercially available standard 50 ml syringes of different compliance.
METHODS
The test assembly consisted of an IVAC syringe pump (IVAC-Alaris, IVAC Medical Systems, Hampshire, U.K.), two different 50 ml syringes (BD Plastipak ® 50 ml, Becton Dickinson, Meylan Cedex, France/Fresenius ® Injectomat-Syringe 50 ml, Fresenius AG, Bad Homburg, Germany), a 2 m noncompliant infusion line (Injectomat-Line, Fresenius AG, Bad Homburg, Germany). A 75 mm opening pressure antisiphon valve infusion line (Safe Guard 1 Line, Vygon, Cirencester, U.K.) or a 155 mmHg opening pressure antisiphon valve infusion line (Protect-A-Line 1, Vygon, Cirencester, U.K.) was connected to the distal end of the 2 m infusion line. The control assembly contained no antisiphon valve. The distal tip of the infusion line of each assembly was immersed into a sampling glass filled with sterile water. The water surface was covered with a thin layer of oil to avoid fluid evaporation. The assembly was flushed and cleared of remaining air bubbles. Fluid delivery into the glass was measured gravimetrically by an electronic balance with 0.0001 g sensitivity (AG 204-Delta-Range ® , Mettler Toledo, Schwerzenbach, Switzerland) 5 . The balance data output was recorded in one second intervals by an IBM-compatible personal computer employing purpose-written software (MCPS V2.6-CAD, Software GmbH, Mönchengladbach, Germany).
Before starting measurements, the syringe outlet and the ASV was positioned level with the infusion line leading into the sampling glass. After obtaining steady state flow conditions at 1 ml/h infusion rate the syringe pump was lowered by 50 cm. The resulting retrograde aspiration volume was recorded (volume retracted into the syringe pump system after lowering) as well as the zero-drug delivery time (the period between lowering of the syringe pump and regaining of the initial weight on the balance). After resuming steady state flow delivery, the pump was re-elevated to its original position and the infusion bolus resulting from relieving the hydrostatic pressure was measured. All experiments were replicated six times at 25°C ambient temperature.
The assembly compliance was determined after introducing a three-way stopcock attached to a blood pressure transducer between the proximal 2 m infusion line and an additional distal 50 cm infusion line. The stopcock was turned to obstruct the syringe outflow and reopened at an occlusion pressure of 100 mmHg. The resulting infusion bolus was measured gravimetrically as described above. Compliance was calculated from dividing the occlusion release bolus by the occlusion pressure.
Data analysis: All experiments were performed in triplicate using two examples of each ASV and two syringes of each manufacturing brand (six measurements per experiment and syringe brand). Retrograde aspiration volume, zero-drug delivery time and infusion bolus were compared across syringe brands, syringes and antisiphon valves by three-way analysis of variance with repeated measures using Schaeffe's correction for multiple testing. All tests were calculated on the Statistical Analysis Software package (SAS Version 6.12, SAS Inc., Cary, NC).
RESULTS
The main finding of the study is that addition of an antisiphon valve significantly prolongs zero-drug delivery time after vertical displacement of the syringe pump by 50 cm (F=52.6, df=2/33, r 2 =0.90, P<0.0001; all comparisons to no valve P<0.001). Without an antisiphon valve the observed zero-drug delivery times after lowering the syringe pump amounted to (mean±SD) 2.4±0.2 min using the BD Plastipak ® syringe and to 4.09±0.55 min using the Fresenius syringe. Introduction of an antisiphon valve prolonged the zero drug delivery time by 58% (ASV 75) and 88% (ASV 155) in the BD Plastipak ® syringe assembly and by 43% (ASV 75) and 81% (ASV 155) in the Fresenius syringe assembly (Figure 1) .
Moreover, when antisiphon valves were used, the prolonged zero-drug delivery time was followed by the rapid delivery of a valve re-opening bolus. These boluses ranged from 10.75±2.72 µl up to 32. Introduction of the antisiphon valves, however, prevented retrograde aspiration of fluid into the syringe assembly after lowering the syringe pump. Without the valve, this retrograde aspiration bolus amounted to 11.88±0.61 µl with the BD Plastipak ® syringe assembly and to 21.95±2.57 µl with the Fresenius syringe assembly. This difference was fully explained by the corresponding difference in assembly compliance (F=109.1, df=1/34, r 2 =0.91, P<0.0001).
Effect of introduction of an antisiphon valve into the infusion pathway: zero-drug delivery time, aspiration volume, opening bolus and infusion bolus during temporary vertical infusion pump displacement of 50 cm at an infusion rate of 1 ml/h
Re-elevation of the syringe pump to its original level after regaining steady state flow conditions resulted in similar infusion boluses whether antisiphon valves were used or not. Data for each syringe and antisiphon valve are presented in Table 1 .
DISCUSSION
We studied whether introduction of antisiphon valves may ameliorate the drug delivery irregularities, which occur after moderate vertical displacement of syringe pumps (lowering and re-elevation by 50 cm). The main findings were that antisiphon valves prevented aspiration boluses after lowering of the syringe pump but caused a considerable prolongation of zero-drug delivery times (43 to 88%). At an infusion rate of 1 ml/h the observed zero-drug delivery times without ASV ranged from 2.4 to 4.1 min depending on the syringe compliance and were probably clinically relevant. Antisiphon valves appear to require an additional opening pressure beyond the valve's operating pressure. The time elapsing until this additional reopening pressure is reached accounts for the prolongation of zero-drug delivery times. After reopening of the valve, a small infusion jet is released. At an infusion rate of 1 ml/h this jet bolus is equivalent to 0.6 to 2 min of infusion time. If potent vasoactive drugs with short half-life times are administered, this bolus following zero-drug delivery may further increase the risk of haemodynamic instability. Thus, the use of antisiphon valves to ameliorate flow irregularities at slow infusion rates cannot be recommended. In addition, pressure extension using antisiphon devices with syringe infusion systems at low infusion rate increases the time from start to initial flow from syringe pumps as recently reported by McCaroll et al 6 .
Whether the observed prevention of aspiration boluses translates into relevant clinical outcomes or cost-savings (e.g., reduced incidence of thrombus formation from retrograde blood aspiration into the catheter) remains to be elucidated.
Antisiphon valves were developed to avoid patient hazard from passive emptying of drugs from assemblies in patient-controlled analgesia [7] [8] [9] . Moreover, half-lives of drugs used in patient-controlled analgesia are several times longer than the observed zero-drug delivery times. Thus, in patient-controlled analgesia, even large vertical displacements of syringe pumps and the associated prolongation of zero-drug delivery times with valves will cause negligible clinical effects.
The limitation of this study is that our measurements were restricted to two antisiphon valves of medium operating pressure. It is theoretically conceivable that antisiphon valves operating at a higher pressure (e.g., >250 mmHg) may show different performance characteristics due to operation at a different point on the volume-pressure curve of the syringe-syringe pump assembly. However, most syringe pumps are not designed for routine operation at these high pressures.
This study only evaluated flow irregularities from a situation of first lowering and then elevating the pump system, which resembled the one most frequently encountered in the care of our patients. Because the volume-pressure curve of the tested infusion assemblies seems to be linear within moderate hydrostatic pressure changes, we suggest that elevating the pump first and then lowering the pump would result in similar values.
CONCLUSION
Antisiphon valves considerably affect the consistency of drug delivery when 50 ml standard syringes are vertically displaced. Therefore their use cannot be recommended when highly concentrated vasoactive drugs with short half-life times are administered at low infusion rates.
